How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Nvidia's positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across ...

Recursion Pharmaceuticals Inc. stock reached a 52-week low, hitting $3.78, underscoring a challenging year for the company. Over the past 12 months, the stock has experienced a significant decline, ...

All the Latest Game Footage and Images from Soul Recursion Soul Recursion is a story focused hack and slash challenging you to explore and uncover the mysteries hidden amongst utopian ruins. Games ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...